Eli Lilly’s diabetes drug tirzepatide gets approval in China

Eli Lilly’s diabetes drug tirzepatide gets approval in China

|Riah Marton|



ELI Lilly said on Tuesday (May 21) its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.

Posted in

Riah Marton

I'm Riah Marton, a dynamic journalist for Forbes40under40. I specialize in profiling emerging leaders and innovators, bringing their stories to life with compelling storytelling and keen analysis. I am dedicated to spotlighting tomorrow's influential figures.

Leave a Comment